Psoriasis is a systemic chronic skin disorder characterized by excessive keratinocyte proliferation that results into thickened scaly plaques, itching and inflammatory changes in the epidermis and dermis. It is transmitted genetically but can be provoked by environmental factors.
It is found in approximately 2% of the population that primarily affects the skin and joints.
It is associated with other inflammatory disorders and autoimmune diseases (eg psoriatic arthritis, inflammatory bowel disease, coronary artery disease).
Generally, it begins as red scaling papules that coalesce to form round-to-oval plaques. The rashes are often pruritic and may be painful.
The oral TYK2/JAK1 inhibitor PF-06700841 appears to be effective in the treatment of patients with moderate-to-severe plaque psoriasis, with a tolerable safety profile, according to the results of a phase IIa study.
The use of fish oil and its components may yield favourable effects on psoriasis and its comorbidities, namely obesity, cardiovascular disease and metabolic disease, when combined with conventional treatments, as reported in a recent study.
Treatment with tumour necrosis factor-alpha (TNFα) inhibitor may likely lead to an increase in body weight and body mass index (BMI) in patients with psoriasis, whereas treatment with anti-interleukin (IL)-12/23 and IL-17 biologics does not, results of a recent systematic review and meta-analysis have shown.
Biologic therapies for psoriasis may need to be switched between classes to increase drug survival in patients, suggest a recent study. Ad hoc retrospective studies are needed to confirm the benefits of this switching strategy.
The first-in-class interleukin (IL)-17A monoclonal antibody secukinumab is a safe and effective treatment for moderate-to-severe plaque psoriasis, with efficacy rates similar to those found in its phase III studies and enduring up to a year from start of treatment.
The risk of serious infection* among patients receiving systemic therapy for psoriasis differs by treatment, with apremilast, etanercept, and ustekinumab associated with a reduced risk of serious infection than methotrexate, according to an observational study.
New drug applications approved by US FDA as of 16 - 30 April 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
Psoriasis appears to be a risk factor for mortality from all causes in a dose-response manner with disease severity and from several specific causes, suggest the results of a systematic review and meta-analysis.
A bidirectional association exists between alopecia areata (AA) and major depressive disorder (MDD) among probands and unaffected siblings, reveals a study. This suggests that shared familial mechanisms tend to cause AA and MDD.